148 related articles for article (PubMed ID: 2934516)
1. In vitro and in vivo irreversible blockade of cortical S2 serotonin receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline: a technique for investigating S2 serotonin receptor recovery.
Battaglia G; Norman AB; Newton PL; Creese I
J Neurochem; 1986 Feb; 46(2):589-93. PubMed ID: 2934516
[TBL] [Abstract][Full Text] [Related]
2. Behavioral and radioligand binding evidence for irreversible dopamine receptor blockade by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline.
Hamblin MW; Creese I
Life Sci; 1983 May; 32(19):2247-55. PubMed ID: 6133202
[TBL] [Abstract][Full Text] [Related]
3. In vivo EEDQ dose-dependently inactivates rat brain 5-HT receptors but not 5-HT uptake sites.
Pinto W; Battaglia G
Neuroreport; 1993 Oct; 5(1):61-4. PubMed ID: 8280861
[TBL] [Abstract][Full Text] [Related]
4. Irreversible antagonism of 5HT2c receptors by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ).
Ni YG; Camacho N; Miledi R
Proc Natl Acad Sci U S A; 1997 Mar; 94(6):2715-8. PubMed ID: 9122262
[TBL] [Abstract][Full Text] [Related]
5. Effects of in vivo and in vitro treatments with N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline on putative muscarinic receptor subtypes in rat brain.
Norman AB; Creese I
Mol Pharmacol; 1986 Aug; 30(2):96-103. PubMed ID: 3755499
[TBL] [Abstract][Full Text] [Related]
6. N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) administration for studies of 5-HT1A receptor binding site inactivation and turnover.
Keck BJ; Lakoski JM
Brain Res Brain Res Protoc; 1997 Oct; 1(4):364-70. PubMed ID: 9384817
[TBL] [Abstract][Full Text] [Related]
7. Down regulation of serotonin-S2 receptor sites in rat brain by chronic treatment with the serotonin-S2 antagonists: ritanserin and setoperone.
Leysen JE; Van Gompel P; Gommeren W; Woestenborghs R; Janssen PA
Psychopharmacology (Berl); 1986; 88(4):434-44. PubMed ID: 3010361
[TBL] [Abstract][Full Text] [Related]
8. Differential modification of striatal D1 dopamine receptors and effector moieties by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vivo and in vitro.
Hess EJ; Battaglia G; Norman AB; Creese I
Mol Pharmacol; 1987 Jan; 31(1):50-7. PubMed ID: 3100940
[TBL] [Abstract][Full Text] [Related]
9. Receptor-binding properties in vitro and in vivo of ritanserin: A very potent and long acting serotonin-S2 antagonist.
Leysen JE; Gommeren W; Van Gompel P; Wynants J; Janssen PF; Laduron PM
Mol Pharmacol; 1985 Jun; 27(6):600-11. PubMed ID: 2860558
[TBL] [Abstract][Full Text] [Related]
10. Regional heterogeneity of serotonin(1A) receptor inactivation and turnover in the aging female rat brain following EEDQ.
Keck BJ; Lakoski JM
Neuropharmacology; 2000 Apr; 39(7):1237-46. PubMed ID: 10760365
[TBL] [Abstract][Full Text] [Related]
11. N-(p-isothiocyanatophenethyl)spiperone, a selective and irreversible antagonist of D2 dopamine receptors in brain.
Xu SX; Hatada Y; Black LE; Creese I; Sibley DR
J Pharmacol Exp Ther; 1991 May; 257(2):608-15. PubMed ID: 1674530
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on various 5-HT receptor binding sites in the rat brain.
Gozlan H; Laporte AM; Thibault S; Schechter LE; Bolaños F; Hamon M
Neuropharmacology; 1994; 33(3-4):423-31. PubMed ID: 7984280
[TBL] [Abstract][Full Text] [Related]
13. Modification of gamma-aminobutyric acidA receptor binding and function by N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline in vitro and in vivo: effects of aging.
Miller LG; Lumpkin M; Galpern WR; Greenblatt DJ; Shader RI
J Neurochem; 1991 Apr; 56(4):1241-7. PubMed ID: 1848276
[TBL] [Abstract][Full Text] [Related]
14. Selective unilateral inactivation of striatal D1 and D2 dopamine receptor subtypes by EEDQ: turning behavior elicited by D2 dopamine receptor agonists.
Giorgi O; Biggio G
Brain Res; 1990 Nov; 533(1):53-9. PubMed ID: 1982234
[TBL] [Abstract][Full Text] [Related]
15. Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists.
Meller E; Goldstein M; Bohmaker K
Mol Pharmacol; 1990 Feb; 37(2):231-7. PubMed ID: 1968223
[TBL] [Abstract][Full Text] [Related]
16. Inactivation of 5-HT(1A) receptors in hippocampal and cortical homogenates.
Alper RH; Nelson DL
Eur J Pharmacol; 2000 Feb; 390(1-2):67-73. PubMed ID: 10708708
[TBL] [Abstract][Full Text] [Related]
17. Modulation of the serotonin S2-receptor in brain after chronic lithium.
Wajda IJ; Banay-Schwartz M; Manigault I; Lajtha A
Neurochem Res; 1986 Jul; 11(7):949-57. PubMed ID: 2944024
[TBL] [Abstract][Full Text] [Related]
18. Effect of aging on recovery of striatal dopamine receptors following N-ethoxycarbonyl-2-ethoxy-1, 2-dihydroquinoline (EEDQ) blockade.
Henry JM; Roth GS
Life Sci; 1984 Aug; 35(8):899-904. PubMed ID: 6482680
[TBL] [Abstract][Full Text] [Related]
19. Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes.
Yocca FD; Iben L; Meller E
Mol Pharmacol; 1992 Jun; 41(6):1066-72. PubMed ID: 1352034
[TBL] [Abstract][Full Text] [Related]
20. Differential effect of N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) on [3H]SCH23390 and [3H]forskolin binding in rat striatum.
Norman AB; Wachendorf TJ; Sanberg PR
Life Sci; 1989; 44(13):831-6. PubMed ID: 2648096
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
